Fundraising Fox

Kivu Bioscience

26 employees on LinkedIn · 6 known investors

Kivu Bioscience develops antibody-drug conjugate (ADC) therapeutics in clinical development, advancing a pipeline of cancer treatments through strategic partnerships and collaborations.

BiotechDeep TechHealthtechMedical Devices

Founders & leadership

MTMohit Trikha
Mohit TrikhainCEO
SRSophia Randolph
Sophia RandolphinChief Medical Officer

Investors · 6

BOMTilburg · $540K – $5.4M
HealthCapStockholm
M VenturesLos Angeles · $10.8M
Red Tree VentureSan Diego
BioGeneration Venturesreported · 2 sourcesNaarden
Novo Holdingsreported · 2 sourcesCopenhagen · $1.1M – $54M

Funding

SEC filings, press & company announcements

$92M disclosed across 1 round · 2024

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Kivu Bioscience Raises $92 Million Series a Led by Novo Holdings to Advance Next-Generation Antibody-Drug Conjugates | MarketScreenermarketscreener.com · Oct 2024BioGeneration Ventures-Founded Kivu Bioscience Secures $92 Million Series A to Advance Next-Generation Antibody-Drug Conjugates | BioGeneration Venturesbiogenerationventures.com · Oct 2024Kivu Bioscience Raises $92M in Series A Fundingfinsmes.com · Oct 2024

Frequently asked questions

What does Kivu Bioscience do?
Kivu Bioscience develops antibody-drug conjugate (ADC) therapeutics in clinical development, advancing a pipeline of cancer treatments through strategic partnerships and collaborations.
Who are Kivu Bioscience's investors?
Kivu Bioscience's investors include BOM, HealthCap, M Ventures, Red Tree Venture, BioGeneration Ventures, Novo Holdings.
How much funding has Kivu Bioscience raised?
Kivu Bioscience has disclosed $92M raised across 1 round.